CCO Treatment Updates

Imatinib Resistance in the Treatment of Chronic Myeloid Leukemia: Current Management Options and Emerging Therapies

Imatinib Resistance in the Treatment of Chronic Myeloid Leukemia: Current Management Options and Emerging Therapies

Module 1 of 1

Faculty:

Elias Jabbour, MD headshotJorge E. Cortes, MD headshotHagop M. Kantarjian, MD headshot
  • Elias Jabbour, MD
  • Jorge E. Cortes, MD
  • Hagop M. Kantarjian, MD

CME CREDIT INFORMATION

Release Date: 09/06/07

Expiration Date: 09/05/08


Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Elias Jabbour, MD; Jorge E. Cortes, MD; and Hagop M. Kantarjian, MD, discuss current and evolving treatments for chronic myeloid leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the pathophysiology of Philadelphia-chromosome positive CML, including the mechanisms by which resistance to standard therapy can emerge
  • Describe the activity of tyrosine kinase inhibitors and the rationale for their use in CML
  • Articulate current clinical data on the efficacy of newer oral therapies in the treatment of imatinib-resistant CML
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.